BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Business

  Semler Reports Third Quarter and Year-to-Date 2017 Financial Results

  For the three months ended September 30, 2017, compared to the corresponding period of 2016, Semler had revenue of $3,607,000, an increase of $1,625,000, compared to $1,982,000

  October 31, 2017

   · 

  13 min read
• Business

  Ocular Therapeutix to Report Third Quarter 2017 Financial Results

  Ocular Therapeutix today announced that it will report third quarter 2017 financial results on Tuesday, November 7, 2017.

  October 31, 2017

   · 

  2 min read
• Business

  BIOLASE Appoints Richard B. Lanman to Board of Directors

  The appointment of Dr. Lanman replaces outgoing director Fredrick H. Moll, M.D., who is resigning from the Board effective November 11, 2017, due to his commitments associated with his role as CEO of Auris Surgical Robotics, Inc.

  October 31, 2017

   · 

  5 min read
• Policy

  Spectral Provides Update on FDA Meeting Regarding Its PMA Submission for Toraymyxin

  The meeting consisted of a general discussion of issues identified by the FDA after the first 100 days of regulatory review and suggestions for clarification of those issues.

  October 31, 2017

   · 

  3 min read
• NeuroVive Signs Collaboration Agreement With University of Florida for TBI Biomarker Development

  The research will be conducted at a laboratory at the University of Florida’s McKnight Brain Institute focused on neurotrauma, neuroproteomics and biomarkers research headed by Wang.

  October 31, 2017

   · 

  4 min read
• 

  Policy

  Novartis Submits Application to FDA for Kymriah (Tisagenlecleucel) in Adult Patients With R/R DLBCL, Seeking Second Indication for First-Ever FDA Approved CAR-T Therapy

  If approved, this would be the second indication for Kymriah.

  October 31, 2017

   · 

  13 min read
• Business

  Dr. Reddy’s Q2 and H1 FY18 Financial Results

  Dr. Reddy’s Laboratories today announced its consolidated financial results for the second quarter and half year ended September 30, 2017 under International Financial Reporting Standards.

  October 31, 2017

   · 

  10 min read
• BioForest

  BioLife Solutions and SAVSU Providing Enhanced Cold Chain Technologies for 8 UCSF Clinical Trials of Treg Cell Therapies

  BioLife Solutions today announced both companies are providing their respective enhanced cold chain technologies for use in 8 active and pending clinical trials conducted by the Diabetes Center and Department of Surgery at the UCSF.

  October 31, 2017

   · 

  6 min read
• BioMidwest

  Humanetics Corporation Presents Data on Potential Treatment to Prevent Erectile Dysfunction in Prostate Cancer Patients

  The annual ASTRO meeting was held September 24th through the 27th in San Diego, California and the annual RRS meeting was held October 15th through the 18th in Cancun, Mexico.

  October 31, 2017

   · 

  4 min read
• Business

  Blueprint Medicines Reports Third Quarter 2017 Financial Results

  “In the third quarter, we continued to advance Blueprint Medicines’ broad and diversified portfolio of compelling clinical and research programs through solid execution, rigorous scientific evaluation and disciplined resource management,” said Jeff Albers, CEO of Blueprint Medicines.

  October 31, 2017

   · 

  18 min read